The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer

Abstract To evaluate the performance of the Prostate Health Index (PHI) in magnetic resonance imaging-transrectal ultrasound (MRI-TRUS) fusion prostate biopsy for the detection of clinically significant prostate cancer (csPCa). We prospectively enrolled 164 patients with at least one Prostate Imagin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yu-Hua Fan, Po-Hsun Pan, Wei-Ming Cheng, Hsin-Kai Wang, Shu-Huei Shen, Hsian-Tzu Liu, Hao-Min Cheng, Wei-Ren Chen, Tzu-Hao Huang, Tzu-Chun Wei, I-Shen Huang, Chih-Chieh Lin, Eric Y. H. Huang, Hsiao-Jen Chung, William J. S. Huang, Tzu-Ping Lin
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7b63d5acaec044019801866a983a3c4a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7b63d5acaec044019801866a983a3c4a
record_format	dspace
spelling	oai:doaj.org-article:7b63d5acaec044019801866a983a3c4a2021-12-02T11:37:19ZThe Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer10.1038/s41598-020-78428-62045-2322https://doaj.org/article/7b63d5acaec044019801866a983a3c4a2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-78428-6https://doaj.org/toc/2045-2322Abstract To evaluate the performance of the Prostate Health Index (PHI) in magnetic resonance imaging-transrectal ultrasound (MRI-TRUS) fusion prostate biopsy for the detection of clinically significant prostate cancer (csPCa). We prospectively enrolled 164 patients with at least one Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) ≥ 3 lesions who underwent MRI-TRUS fusion prostate biopsy. Of the PSA-derived biomarkers, the PHI had the best performance in predicting csPCa (AUC 0.792, CI 0.707–0.877) in patients with PI-RADS 4/5 lesions. Furthermore, the predictive power of PHI was even higher in the patients with PI-RADS 3 lesions (AUC 0.884, CI 0.792–0.976). To minimize missing csPCa, we used a PHI cutoff of 27 and 7.4% of patients with PI-RADS 4/5 lesions could have avoided a biopsy. At this level, 2.0% of cases with csPCa would have been missed, with sensitivity and NPV rates of 98.0% and 87.5%, respectively. However, the subgroup of PI-RADS 3 was too small to define the optimal PHI cutoff. PHI was the best PSA-derived biomarker to predict csPCa in MRI-TRUS fusion prostate biopsies in men with PI-RADS ≥ 3 lesions, especially for the patients with PI-RADS 3 lesions who gained the most value.Yu-Hua FanPo-Hsun PanWei-Ming ChengHsin-Kai WangShu-Huei ShenHsian-Tzu LiuHao-Min ChengWei-Ren ChenTzu-Hao HuangTzu-Chun WeiI-Shen HuangChih-Chieh LinEric Y. H. HuangHsiao-Jen ChungWilliam J. S. HuangTzu-Ping LinNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yu-Hua Fan Po-Hsun Pan Wei-Ming Cheng Hsin-Kai Wang Shu-Huei Shen Hsian-Tzu Liu Hao-Min Cheng Wei-Ren Chen Tzu-Hao Huang Tzu-Chun Wei I-Shen Huang Chih-Chieh Lin Eric Y. H. Huang Hsiao-Jen Chung William J. S. Huang Tzu-Ping Lin The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer
description	Abstract To evaluate the performance of the Prostate Health Index (PHI) in magnetic resonance imaging-transrectal ultrasound (MRI-TRUS) fusion prostate biopsy for the detection of clinically significant prostate cancer (csPCa). We prospectively enrolled 164 patients with at least one Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) ≥ 3 lesions who underwent MRI-TRUS fusion prostate biopsy. Of the PSA-derived biomarkers, the PHI had the best performance in predicting csPCa (AUC 0.792, CI 0.707–0.877) in patients with PI-RADS 4/5 lesions. Furthermore, the predictive power of PHI was even higher in the patients with PI-RADS 3 lesions (AUC 0.884, CI 0.792–0.976). To minimize missing csPCa, we used a PHI cutoff of 27 and 7.4% of patients with PI-RADS 4/5 lesions could have avoided a biopsy. At this level, 2.0% of cases with csPCa would have been missed, with sensitivity and NPV rates of 98.0% and 87.5%, respectively. However, the subgroup of PI-RADS 3 was too small to define the optimal PHI cutoff. PHI was the best PSA-derived biomarker to predict csPCa in MRI-TRUS fusion prostate biopsies in men with PI-RADS ≥ 3 lesions, especially for the patients with PI-RADS 3 lesions who gained the most value.
format	article
author	Yu-Hua Fan Po-Hsun Pan Wei-Ming Cheng Hsin-Kai Wang Shu-Huei Shen Hsian-Tzu Liu Hao-Min Cheng Wei-Ren Chen Tzu-Hao Huang Tzu-Chun Wei I-Shen Huang Chih-Chieh Lin Eric Y. H. Huang Hsiao-Jen Chung William J. S. Huang Tzu-Ping Lin
author_facet	Yu-Hua Fan Po-Hsun Pan Wei-Ming Cheng Hsin-Kai Wang Shu-Huei Shen Hsian-Tzu Liu Hao-Min Cheng Wei-Ren Chen Tzu-Hao Huang Tzu-Chun Wei I-Shen Huang Chih-Chieh Lin Eric Y. H. Huang Hsiao-Jen Chung William J. S. Huang Tzu-Ping Lin
author_sort	Yu-Hua Fan
title	The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer
title_short	The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer
title_full	The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer
title_fullStr	The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer
title_full_unstemmed	The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer
title_sort	prostate health index aids multi-parametric mri in diagnosing significant prostate cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/7b63d5acaec044019801866a983a3c4a
work_keys_str_mv	AT yuhuafan theprostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT pohsunpan theprostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT weimingcheng theprostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT hsinkaiwang theprostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT shuhueishen theprostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT hsiantzuliu theprostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT haomincheng theprostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT weirenchen theprostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT tzuhaohuang theprostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT tzuchunwei theprostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT ishenhuang theprostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT chihchiehlin theprostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT ericyhhuang theprostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT hsiaojenchung theprostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT williamjshuang theprostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT tzupinglin theprostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT yuhuafan prostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT pohsunpan prostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT weimingcheng prostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT hsinkaiwang prostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT shuhueishen prostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT hsiantzuliu prostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT haomincheng prostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT weirenchen prostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT tzuhaohuang prostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT tzuchunwei prostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT ishenhuang prostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT chihchiehlin prostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT ericyhhuang prostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT hsiaojenchung prostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT williamjshuang prostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer AT tzupinglin prostatehealthindexaidsmultiparametricmriindiagnosingsignificantprostatecancer
_version_	1718395767956176896

The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer

Ejemplares similares